Ergos Life Sciences Private Limited - Due diligence report

A 360° intelligence report on Ergos Life Sciences: trust score, financial health, credit view, compliance, directors, growth and distress si…

2017-03-21 Mumbai, Maharashtra Active Unlisted Active Compliant
Share
EL Ergos Life Sciences Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Ergos Life Sciences — 360° Intelligence Report

Generated from MCA filings & public records
51/100
Trust Score
Moderate

Ergos Life Sciences is assessed as Moderate with a Trust Score of 51/100. Ergos Life Sciences is an active private limited indian non-government company incorporated in 2017, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and high financial risk profile.

Report generated on 16 Jul 2026 from the latest processed filings. Ergos Life Sciences Private Limited snapshot & full profile →

Financial Health › Caution
Overall Assessment CautionWeakNeutralGoodStrong Neutral
Compliance › Good

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
51/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
60/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
5/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
65/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
30/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 4 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 60/100 Moderate
  • Company status is Active as per MCA.
  • Last balance sheet is for Mar 2023 - filings overdue.
  • Litigation present in 1 court forum(s).
  • Delayed payments to MSME suppliers disclosed (1 disclosure(s)).
  • 1 active GST registration(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
SAKTI PADA CHAKRABORTY 01234567 Director 01/04/2018 6 yrs Approved
SAKTI PADA CHAKRABORTY 01234567 Director 01/04/2018 6 yrs Approved
CHETAN SHYAMLAL CHANDWANI 01234567 Director 01/04/2018 6 yrs Approved
VINAY RAMAKANT SAPTE 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Maneesh Pharmaceuticals Limited
Subsidiaries
-
Group entities
-
Capital events
2 allotment(s) · 4 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Maneesh Pharmaceuticals Limited Holding Company 74.00%

Key managerial personnel: SAKTI PADA CHAKRABORTY (CEO)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 65 · Distress 30
Growth signals & trust indicators
Steady revenue growth: +38% over 3 year(s).
EPFO headcount growing - hiring signal.
Operating for 9 years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
Negative net worth.
Statutory filings appear overdue.
MSME payment delays disclosed - latest outstanding 1.46 Lakh.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence48/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 4 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment37/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance gaps should be priced into terms.
Investor view40/100
Limited indicators at present
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
11 Jul 2023
Last AGM held
Annual general meeting
31 Mar 2023
Latest balance sheet
Filed with ROC
16 Mar 2023
Director appointed
CHETAN SHYAMLAL CHANDWANI (Company Secretary)
31 Mar 2021
Share transfer (FY 2021)
3000.00000000 shares to Maneesh Pharmaceuticals Limited
Share transfer (FY 2021)
180000.00000000 shares to Maneesh Pharmaceuticals Limited
Share transfer (FY 2021)
20000.00000000 shares to Maneesh Pharmaceuticals Limited
26 Feb 2019
Securities allotted
25000000 Preference Shares - 25.00 cr raised
31 Mar 2018
Share transfer (FY 2018)
30000.00000000 shares to Abir samarendra Chaudhuri
29 Aug 2017
Securities allotted
35000000 Preference Shares - 35.00 cr raised
03 Aug 2017
Director ceased
SANYUKTA CHAKRABORTY
10 Apr 2017
Director appointed
SAKTI PADA CHAKRABORTY (CEO)
Director ceased
SAKTI PADA CHAKRABORTY
01 Apr 2017
Director appointed
SAKTI PADA CHAKRABORTY (Director)
21 Mar 2017
Incorporated
Registered with Roc Mumbai
Director appointed
VINAY RAMAKANT SAPTE (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 1.42 over the last 3 financial year(s).
Net profit margin moved from 2.1x to 24%.
4 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Suvikhitek U24231GJ1977PTC003036 Ahmadabad City, Gujarat, India
Star Alloys & Chemicals Private Limited U27101CT2008PTC020561 Korba, Chattisgarh, India
G.R. Movers Private Limited U60231UP2008PTC036383 Shahjahanpur, Uttar Pradesh, India
Brindavan Phosphates Private Limited U24111KA1991PTC012510 Bangalore, Karnataka, India
Sauss Home Products Private Limited U24100UP2014PTC062466 Shikohabad, Uttar Pradesh, India
Reagens India Polymer Additives Private Limited U24304GJ2018PTC148309 Vagra, Gujarat, India
Deccan Explotech Private Limited U24292PN2008PTC131264 Pune, Maharashtra, India
Thermochem Processes Private Limited U24119PN2005PTC021507 Dist: Kolhapur - 416 324, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Ergos Life Sciences before audits and certifications: compliance score 60/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Ergos Life Sciences: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Enhanced diligence advised. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Limited indicators at present. Growth score 65/100, margin trends, ownership structure and peer set for Ergos Life Sciences - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 51/100, distress signals and MSME payment-delay disclosures - know whether Ergos Life Sciences pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Ergos Life Sciences - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Ergos Life Sciences an active company?

Ergos Life Sciences has MCA status “Active” with a compliance score of 60/100 (Moderate).

Is Ergos Life Sciences financially healthy?

Ergos Life Sciences has a Financial Health Score of 5/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Ergos Life Sciences?

Its overall Trust Score is 51/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Ergos Life Sciences?

The ultimate holding entity is Maneesh Pharmaceuticals Limited. 4 active director(s) are on record.

Does Ergos Life Sciences have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Ergos Life Sciences up to date with its ROC filings?

Last balance sheet is for Mar 2023 - filings overdue. Overall compliance score: 60/100 (Moderate).

Is it risky to lend to Ergos Life Sciences?

Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.